Letermovir Pill

DRUG3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, University Medical Centre Ljubljana, The First Affiliated Hospital of Soochow University

Conditions

CMVCMV InfectionCMV ViremiaHematopoietic Cell TransplantHematopoietic Stem Cell Transplantation

Phase 2

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

CompletedNCT04017962

Memorial Sloan Kettering Cancer CenterCMV, CMV Infection, Hematopoietic Cell Transplant

Start: 2019-07-19End: 2025-07-29Updated: 2025-08-11

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

RecruitingNCT05432778

University Medical Centre LjubljanaCMV Viremia

Start: 2023-05-01End: 2026-08-01Target: 90Updated: 2023-11-09

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

The First Affiliated Hospital of Soochow UniversityCMV Infection, Hematopoietic Stem Cell Transplantation

Start: 2022-07-07End: 2025-09-01Target: 80Updated: 2023-09-01

Related Papers

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study

Open Forum Infectious Diseases2021-11-014 citations